In vitro activity of alpha-viniferin isolated from the roots of Carex humilis against Mycobacterium tuberculosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seo, Hoonhee | - |
dc.contributor.author | Kim, Mijung | - |
dc.contributor.author | Kim, Sukyung | - |
dc.contributor.author | Al Mahmud, Hafij | - |
dc.contributor.author | Islam, Md Imtiazul | - |
dc.contributor.author | Nam, Kung-Woo | - |
dc.contributor.author | Cho, Myoung-Lae | - |
dc.contributor.author | Kwon, Hyun-Sook | - |
dc.contributor.author | Song, Ho-Yeon | - |
dc.date.accessioned | 2021-08-11T14:24:14Z | - |
dc.date.available | 2021-08-11T14:24:14Z | - |
dc.date.issued | 2017-10 | - |
dc.identifier.issn | 1094-5539 | - |
dc.identifier.issn | 1522-9629 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7154 | - |
dc.description.abstract | This study explores the antitubercular activity of alpha-viniferin, a bioactive phytochemical compound obtained from Carex humilis. alpha-Viniferin was active against both drug-susceptible and -resistant strains of Mycobacterium tuberculosis at MIC(50)s of 4.6 mu M in culture broth medium and MIC(50)s of 2.3-4.6 mu M inside macrophages and pneumocytes. In combination with streptomycin and ethambutol, alpha-viniferin exhibited an additive effect and partial synergy, respectively, against M. tuberculosis H37Rv. alpha-Viniferin also did not show cytotoxicity in any of the cell lines tested up to a concentration of 147 M, which gives this compound a selectivity index of >32. Moreover, alpha-viniferin was active against 3 Staphylococcus species, including methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), and methicillin-resistant Staphylococcus epidermidis (MRSE). (C) 2017 Elsevier Ltd. All rights reserved. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Academic Press | - |
dc.title | In vitro activity of alpha-viniferin isolated from the roots of Carex humilis against Mycobacterium tuberculosis | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1016/j.pupt.2017.08.003 | - |
dc.identifier.scopusid | 2-s2.0-85028082919 | - |
dc.identifier.wosid | 000413177500006 | - |
dc.identifier.bibliographicCitation | Pulmonary Pharmacology and Therapeutics, v.46, pp 41 - 47 | - |
dc.citation.title | Pulmonary Pharmacology and Therapeutics | - |
dc.citation.volume | 46 | - |
dc.citation.startPage | 41 | - |
dc.citation.endPage | 47 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordPlus | ANTIMYCOBACTERIAL ACTIVITY | - |
dc.subject.keywordPlus | ANTIMICROBIAL ACTIVITIES | - |
dc.subject.keywordPlus | STILBENE OLIGOMERS | - |
dc.subject.keywordPlus | HUMAN MACROPHAGE | - |
dc.subject.keywordPlus | AVIUM | - |
dc.subject.keywordPlus | (+)-ALPHA-VINIFERIN | - |
dc.subject.keywordPlus | CLARITHROMYCIN | - |
dc.subject.keywordPlus | RESISTANT | - |
dc.subject.keywordPlus | KRM-1648 | - |
dc.subject.keywordPlus | COMPLEX | - |
dc.subject.keywordAuthor | Mycobacterium tuberculosis | - |
dc.subject.keywordAuthor | alpha-Viniferin | - |
dc.subject.keywordAuthor | Carex humilis | - |
dc.subject.keywordAuthor | XDR | - |
dc.subject.keywordAuthor | MRSA | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.